![](images/null.gif) |
![](images/null.gif) |
![](images/null.gif) |
|
PREDICTABILITY OF SERUM HBcrAg, HBsAg AND INTERFERON INDUCIBLE PROTEIN 10 (IP10) LEVELS IN NON-CIRRHOTIC HBeAg-NEGATIVE CHRONIC HEPATITIS B PATIENTS WHO DISCONTINUE ENTECAVIR (ETV) OR TENOFOVIR (TDF) THERAPY:
RESULTS FROM THE PROSPECTIVE DARING-B STUDY
|
|
|
Reported by Jules Levin
AASLD 2018 Nov 9-13 SF
M Papatheodoridi1, E Hadziyannis2, F Berby3, E Rigopoulou4, K Zachou4, B Testoni3, A Lyberopoulou4, N Gatselis4, J Vlachogiannakos1, S Manolakopoulos1,2, GN Dalekos4, F Zoulim3, GV Papatheodoridis1.
1Department of Gastroenterology, Medical School of National and Kapodistrian University of Athens, Laiko General Hospital, Athens, Greece; 2Department of Medicine and Research Laboratory of Internal Medicine, Thessaly University Medical School, Larissa, Greece; 3Department of Hepatology, Hospices Civils de Lyon, CRCL-INSERM U1052, Lyon University, Lyon, France;42nd Department of Internal Medicine, Medical School of National and Kapodistrian University of Athens, Hippokratio General Hospital, Athens, Greece.
![0102191](../images%20/010218/010219-2/0102191.gif)
![0102192](../images%20/010218/010219-2/0102192.gif)
![0102193](../images%20/010218/010219-2/0102193.gif)
![0102194](../images%20/010218/010219-2/0102194.gif)
![0102195](../images%20/010218/010219-2/0102195.gif)
![0102196](../images%20/010218/010219-2/0102196.gif)
|
|
|
![](images/null.gif) |
![](images/null.gif) |
|
|